본문으로 건너뛰기
← 뒤로

Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer.

Journal of radiation research 2026 Vol.67(2) p. 236-247

Tominaga Y, Endo H, Kato T, Wakisaka Y, Higashikawa T, Murakami M, Yamamoto M

📝 환자 설명용 한 줄

This study evaluated the feasibility of pencil beam scanning (PBS) proton therapy for stereotactic body radiotherapy using an isodose prescription in patients with isolated early-stage lung cancer, co

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value P < 0.05

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Tominaga Y, Endo H, et al. (2026). Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer.. Journal of radiation research, 67(2), 236-247. https://doi.org/10.1093/jrr/rraf091
MLA Tominaga Y, et al.. "Dosimetric comparison of scanned proton therapy and volumetric modulated arc therapy in isodose-prescribed stereotactic body radiotherapy for lung cancer.." Journal of radiation research, vol. 67, no. 2, 2026, pp. 236-247.
PMID 41642715
DOI 10.1093/jrr/rraf091

Abstract

This study evaluated the feasibility of pencil beam scanning (PBS) proton therapy for stereotactic body radiotherapy using an isodose prescription in patients with isolated early-stage lung cancer, comparing dose-volume metrics with those of volumetric modulated arc therapy (VMAT). Treatment plans were generated for 10 patients with tumors located at least 2 cm from the trachea. Each plan prescribed 48 Gy(RBE) in four fractions with a 60% isodose prescription. Both multi-field optimized and single-field optimized PBS plans used four fields, while VMAT plans used two coplanar arcs. Plan robustness was assessed by simulating setup errors of ±5.0 mm and density uncertainties of ±3.5%, with worst-case target coverage also analyzed. Comparisons among the three planning strategies employed Bonferroni-adjusted multiple comparisons for target coverage, robustness, and organ-at-risk doses. PBS achieved target coverage comparable to VMAT, with similar D98% (63.2 ± 1.3 GyRBE vs. 64.0 ± 1.6 Gy; P = 0.12), mean doses (73.2 ± 0.8 GyRBE vs. 73.7 ± 1.2 Gy; P = 0.21), and robustness (D98%: 50.2 ± 0.9 GyRBE vs. 50.3 ± 1.1 Gy; P = 0.77). For the normal lung, PBS significantly reduced low-dose exposure up to V10Gy, whereas VMAT was more effective in reducing doses from V20Gy to the prescription level. All evaluated organ-at-risks received significantly lower mean doses with PBS than with VMAT (P < 0.05). Under a 60% isodose prescription for lung stereotactic body radiotherapy, multi-field optimized-based PBS proton therapy provides target coverage and robustness comparable to VMAT while offering superior normal tissue sparing.

MeSH Terms

Humans; Lung Neoplasms; Radiotherapy, Intensity-Modulated; Radiosurgery; Proton Therapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiometry; Organs at Risk; Male